-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Fudan University School of Public Health, the Joint Task Force Yu Hongjie China Sinovac Biotech Co.
There is a high correlation between the level of neutralizing antibodies induced by the new crown vaccine and the protective effect of the vaccine
The results showed that for the 18-59-year-old population with an interval of 2 months between the second and third doses, compared with 28 days after the second dose, the neutralizing antibody level of the subjects was slightly increased 28 days after the third dose
Figure 1: The level of neutralizing antibodies against the SARS-CoV-2 prototype strain in the adult group of 18-59 years old
For people 60 years of age and older with an interval of 8 months between the second and third doses, the neutralizing antibody titer dropped to close to or below the positive detection threshold 6 months after the two doses of basic immunization
The third dose of the vaccine was well tolerated and there was no difference compared with the first two doses
Figure 2: Levels of neutralizing antibodies against SARS-CoV-2 prototype strains in adults 60 years and older
Results of this study show that Kerr blessing ® is two times the basic immunization can produce a good immune memory
In view of the important public health significance of this research, the journal invited Professor Julio Croda of the Federal University of Mato Grosso do Sul, Brazil, and Otavio T Ranzani, an epidemiologist at the Institute of Global Health in Barcelona, Spain to "Booster doses for inactivated COVID-19 vaccines: "if, when, and for whom" as the topic, wrote an expert review
Kexing Holding Biotechnology Co.
In addition, the research group also co-Yu Hongjie Changping National Laboratory and the Beijing Ditan Hospital conducted a single center over 18 years of medical staff, open, randomized, controlled clinical trial to evaluate the completion of two times Kerr blessing ® foundation 4-8 months after immunization, the third vaccination doses Kerr fu ® or recombinant protein vaccine Zhi Fei (ZF2001) in 14 days and antibody levels
Figure 3.